Natco Pharma has launched a generic version of Posaconazole Injection, 300 mg/16.7ml, under its brand POSANAT.

This is the first time an injection version of this drug is available in India. POSANAT will be available in 18 mg/ml strength, a formulation for intravenous (IV) use.

Posaconazole Injection is sold in the USA market by Merck under its brand name of NOXAFIL.

Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.

The stock ended at Rs786.75 up by Rs21.8 or 2.85% from its previous closing of Rs764.95 on the BSE.

The scrip opened at Rs762 and touched a high and low of Rs792.50 and Rs755.90 respectively.

Natco Pharma, a leading domestic player in the oncology and Hepatitis C, derived 22% of its Q4FY18 sales from domestic markets of which 52% came from oncology business. The company derived 69% revenue from international formulations and rest 8.4% from in Q4FY18.

Domestically, the company is expanding presence in speciality segment with launches of HEPCINAT and HEPCINAT LP for Hepatitis C. It will be focusing on high-value and first-to-market generic drugs in India, Brazil and Canada going ahead. The company has launched two new divisions in India i.e. Cardiology and Diabetology.